Whilst the attenuation of tumour cell growth was observed in DDR-defective neuroblastoma cell lines treated with Olaparib, this effect was not seen in ATM-competent ones, suggesting that pre-existing defects in DNA damage repair pathways increases tumour sensitivity to PARPi [38]. This evidence concerns the gene ATM and neuroblastoma.